Co-pay support programs for expensive drugs have been in the policy news for at least five years (
here,
here). Do they simply help patients with $100 copays, or are they a way of boosting sales of overpriced drugs that have a justifiably poor position on the formulary tier?
Here's an ad for Outcomes and adherence in patient assistance support programs.